This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by D'Cruz, D Search for Related Content PubMed PubMed Citation Articles by D'Cruz, D Pubmed/NCBI databases Medline Plus Health Information Lupus Social Bookmarking                         What's this?

Antimalarial therapy: a panacea for mild lupus?

The Lupus Research Unit, St Thomas' Hospital, London, SE1 7EH, UK,Tel: +44 207 928 9292 Ext 2710; Fax: +44 207 620 2658

Antimalarial therapy has a long and successful track record in the management of patirents with mild SLE. Medium to long term use of hydroxychloroquine, alone or in combination with mepacrine, ameliorates lupus and may reduce the relapse rate. Recent guidelines for monitoring hydroxychloroquine have reduced the need for frequent visual checks. Antimalarials have other beneficial effects on lipid and glucose metabolism as well as having weak anticoagulant activity. They should be considered for most patients with mild lupus.

Key Words: antimalarials • systemic lupus erythematosus • lipids • thrombosis • glucose metabolism

Lupus, Vol. 10, No. 3, 148-151 (2001)
DOI: 10.1191/096120301669779293


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				I Cavazzana, R Sala, C Bazzani, A Ceribelli, C Zane, R Cattaneo, A Tincani, P. Calzavara-Pinton, and F Franceschini Treatment of lupus skin involvement with quinacrine and hydroxychloroquine Lupus, July 1, 2009; 18(8): 735 - 739. [Abstract] [PDF]

				S. Panjwani Early Diagnosis and Treatment of Discoid Lupus Erythematosus J Am Board Fam Med, March 1, 2009; 22(2): 206 - 213. [Abstract] [Full Text] [PDF]

				J. James, X. Kim-Howard, B. Bruner, M. Jonsson, M. McClain, M. Arbuckle, C. Walker, G. Dennis, J. Merrill, and J. Harley Hydroxychloroquine sulfate treatment is associated with later onset of systemic lupus erythematosus Lupus, June 1, 2007; 16(6): 401 - 409. [Abstract] [PDF]

				A Wozniacka, A Lesiak, J Narbutt, J Kobos, S Pavel, and A Sysa-Jedrzejowska Chloroquine treatment reduces the number of cutaneous HLA-DR+ and CD1a+ cells in patients with systemic lupus erythematosus Lupus, February 1, 2007; 16(2): 89 - 94. [Abstract] [PDF]

				C C Mok and C S Lau Lupus in Hong Kong Chinese Lupus, September 1, 2003; 12(9): 717 - 722. [Abstract] [PDF]

				A Wozniacka, A Carter, and D P Mccauliffe Antimalarials in cutaneous lupus erythematosus: mechanisms of therapeutic benefit Lupus, February 1, 2002; 11(2): 71 - 81. [Abstract] [PDF]